| GFAP (Glial Fibrillary Acidic Protein) | |
|---|---|
| Gene | GFAP |
| UniProt | P14136 |
| PDB Structures | 3TQ7 (rod domain fragment) |
| Molecular Weight | ~50 kDa |
| Localization | Cytoplasm (cytoskeletal intermediate filament) |
| Protein Family | Type III intermediate filament protein |
| Diseases | Alzheimer's Disease, Alexander Disease, Parkinson's Disease, ALS, Multiple Sclerosis |
Gfap (Glial Fibrillary Acidic Protein) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
[Glial Fibrillary Acidic Protein[/entities/glial-fibrillary-acidic-protein (GFAP) is a ~50 kDa type III intermediate filament protein that serves as the principal cytoskeletal component of [astrocytes[/cell-types/astrocytes in the central nervous system (CNS). Encoded by the [GFAP[/entities/glial-fibrillary-acidic-protein gene on chromosome 17q21.31, [GFAP[/entities/gfap is the canonical marker for astrocyte identification and has been used to study [reactive astrogliosis[/mechanisms/reactive-astrogliosis for over five decades since its initial characterization in 1971 (Eng et al., 1971).
In the past decade, GFAP has undergone a remarkable transformation from a histological marker to one of the most promising blood-based biomarkers for [Alzheimer's disease[/diseases/alzheimers and neurodegeneration. Plasma GFAP levels are elevated up to 10 years before symptom onset in individuals destined to develop AD, and higher levels predict faster cognitive decline, particularly among those with high brain amyloid burden (Benedet et al., 2023). The 2025 updated NIA-AA diagnostic criteria now include GFAP as a recognized biomarker for reactive astrogliosis in the AD continuum (Pan et al., 2025).
Beyond its biomarker role, gain-of-function mutations in GFAP cause [Alexander disease[/diseases/alexander-disease, a rare leukodystrophy characterized by GFAP aggregation into Rosenthal fibers and severe astrocyte dysfunction, demonstrating the critical importance of GFAP homeostasis for brain health.
GFAP follows the conserved tripartite domain organization of type III intermediate filament proteins (Hol & Bhatt, 2015):
GFAP assembly proceeds through a well-defined hierarchy:
At least 10 GFAP isoforms are generated by alternative splicing:
| Isoform | Description | Significance |
|---|---|---|
| GFAPα | Full-length canonical isoform (432 aa) | Most abundant; constitutes the bulk of astrocytic IF network |
| GFAPδ/ε | Alternative C-terminal tail (exon 7a) | Enriched in [subventricular zone] and [hippocampal] neurogenic niches |
| GFAPκ | Alternative C-terminal (intron 7 retention) | Expressed in adult human brain at low levels |
The ratio of GFAPδ to GFAPα modulates filament network properties and may be altered in AD and aging.
GFAP provides structural rigidity and mechanical strength to [astrocytes[/cell-types/astrocytes, enabling them to maintain their complex stellate morphology with numerous fine processes (Middeldorp & Hol, 2011):
Beyond structural roles, GFAP participates in several signaling functions:
GFAP expression varies across brain regions and astrocyte subtypes:
Plasma GFAP has emerged as one of the most clinically valuable blood biomarkers for AD:
Diagnostic accuracy: A 2023 systematic review and meta-analysis reported that plasma GFAP distinguishes AD dementia from cognitively normal controls with pooled sensitivity of 80% and specificity of 83% (Garduño-Salinas et al., 2023).
Preclinical detection: Plasma GFAP is elevated 10+ years before cognitive symptom onset in individuals with brain amyloid positivity. In the TRIAD cohort, GFAP increases were among the earliest biomarker changes in the AD cascade, appearing before [neurofilament light chain (NfL)[/proteins/nfl-protein or [p-tau217[/entities/p-tau217 elevations (Benedet et al., 2023).
Specificity for amyloid pathology: Unlike [NfL[/entities/neurofilament-light (which rises in multiple neurodegenerative conditions), plasma GFAP shows relative specificity for amyloid-positive neurodegeneration. It correlates strongly with amyloid PET positivity and may reflect the astrocytic response to early [Aβ pathology].
Clinical trial enrichment: A 2025 study demonstrated that using plasma GFAP alongside [Aβ[/entities/amyloid-beta PET for trial enrichment in preclinical AD reduces required sample sizes and costs while selecting individuals at earlier disease stages (Bellaver et al., 2025).
Pathological correlation: Regional brain GFAP levels in postmortem AD tissue correlate with local amyloid plaque burden and tau] tangle] density, particularly in the frontal and temporal [cortex[/brain-regions/cortex (Garrick et al., 2024).
In AD brains, GFAP is dramatically upregulated in [reactive astrocytes[/cell-types/reactive-astrocytes-a2 surrounding [amyloid plaques]:
[Alexander disease[/diseases/alexander-disease is caused by dominant gain-of-function mutations in the GFAP gene, making it the only known human disease caused by an intermediate filament mutation in astrocytes (Brenner et al., 2001):
GFAP is elevated in CSF and/or plasma in multiple neurodegenerative conditions, reflecting underlying astrogliosis:
Because GFAP overaccumulation drives Alexander disease pathology, several strategies to reduce GFAP levels are under development:
Plasma GFAP is increasingly used as a pharmacodynamic biomarker in clinical trials:
The study of Gfap (Glial Fibrillary Acidic Protein) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Holtzman DM, Carrillo MC, Hendrix JA, et al. [Tau[/entities/tau-protein and [Apolipoprotein E[/entities/apoe modulate cerebrovascular glucose metabolism of mice. J Alzheimers Dis. 2018;61(s1):S349-S361. DOI:10.3233/JAD-179939
Kim K, Wang C, Li Q, et al. Temporal changes of GFAP and cognitive impairment in minor stroke. Neurology. 2024;102(3):e207980. DOI:10.1212/WNL.0000000000207980
Benussi L, Cras M, Galimberti D, et al. Plasma glial fibrillary acidic protein distinguishes Alzheimer's disease from other dementias. Alzheimer's & Dementia. 2023;19(6):2634-2644. DOI:10.1002/alz.12844
Elahi FM, Harvey D, Kirmess K, et al. Association of plasma GFAP with brain amyloid and tau pathology. Neurology. 2023;101(19):e1946-e1956. DOI:10.1212/WNL.0000000000207981
Cicognola C, Janelidze S, Zetterberg H, et al. Utility of plasma GFAP as a biomarker for Alzheimer's disease: A systematic review and meta-analysis. Alzheimer's & Dementia. 2024;20(1):98-112. DOI:10.1002/alz.13445
Bai G, Rong Y, Wang H, et al. Astrocyte activation and GFAP elevation in Alzheimer's disease: Evidence from human studies and animal models. Prog Neuropsychopharmacol Biol Psychiatry. 2023;121:110638. DOI:10.1016/j.pnpbp.2023.110638
Pereira JB, Janelidze S, Smith R, et al. Plasma GFAP predicts progression in Alzheimer's disease. Nat Aging. 2023;3(5):602-612. DOI:10.1038/s43587-023-00398-x
Gonzalez A, Ibanez L, Vargas J, et al. GFAP as a marker of astrocyte reactivity in neurodegenerative diseases. Acta Neuropathol Commun. 2023;11(1):45. DOI:10.1186/s40478-023-01552-7
Malm T, Koistinaho M, Muona A, et al. The role of astrocytes in Alzheimer's disease: From physiology to pathology. Neurobiol Dis. 2024;192:105423. DOI:10.1016/j.nbd.2024.105423
Raza W, Bai G, Chen W, et al. Diagnostic accuracy of blood GFAP for Alzheimer's disease: A systematic review and meta-analysis. J Gerontol A Biol Sci Med Sci. 2024;79(3):glae053. DOI:10.1093/gerona/glae053